Physician profile
John Kubasiak
NPI 1346533353
$11,393.00
in general payments reported to CMS, 2019-2025
6 companies · $10K in 2025
The $10K reported for 2025 was more than what 95% of Surgical Critical Care providers received nationally (typical 2025 total: $234).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2021: $232 · 2022: $407 · 2024: $272 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,375 · Travel and Lodging: $2,448 · Food and Beverage: $830 · Education: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,375.00 |
| Travel and Lodging | $2,448.48 |
| Food and Beverage | $829.56 |
| Education | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avita Medical Americas, LLC | $9,610.12 | 2019-2025 | Cohealyx, Recell, Permeaderm |
| Kerecis Limited | $1,209.61 | 2022-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Integra Lifesciences Corporation | $296.00 | 2021-2022 | |
| Polynovo North America LLC | $138.81 | 2022 | |
| Access Pro Medical, LLC | $102.35 | 2025 | Matriderm |
| Acera Surgical, INC. | $36.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kubasiak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.